Dalal Street: Highway Infrastructure, Zydus, Mahindra Stocks Shift

⚡ Key Financial Takeaways

Highway Infrastructure shares rose 8 % after signing a ₹220.66 cr toll‑plaza contract with UP EIDA and receiving a ₹24.46 cr acceptance from NHAI.

Zydus Lifesciences stock fell after HSBC kept a Hold rating, citing the US launch of Saroglitazar as a key R&D milestone.

SML Mahindra shares fell 4 % despite an 18 % year‑on‑year rise in September sales.

Mahindra & Mahindra shares slipped 2 % even as sales grew 15 % YoY, with exports and tractor sales showing weakness.

Lemon Tree Hotels shares climbed 3 % after opening its first Darjeeling hotel, expanding its West Bengal footprint.

💡 Why It Matters

The day’s movements reflect a mix of infrastructure expansion, pharmaceutical milestones, and automotive sales dynamics. Highway Infrastructure’s contract signals continued growth in toll‑plaza operations, a key revenue driver for the sector. Zydus’s stock reaction underscores the importance of regulatory approvals for drug commercialization. Mahindra & Mahindra’s mixed results highlight the challenges of balancing domestic growth with export and tractor sales declines. Lemon Tree Hotels’ expansion demonstrates the hospitality sector’s resilience and geographic diversification.

Highway Infrastructure Gains Highway Infrastructure’s stock surged 8 % on Oct 1 after the company announced a new contract with the Uttar Pradesh Expressways Industrial Development Authority. The deal, worth ₹220.66 cr, will see the firm collect user fees and manage toll plazas on the Gorakhpur Link Expressway. In a separate development, the National Highways Authority of India issued a Letter of Acceptance worth ₹24.46 cr for operations at the Velanchettiyur Fee Plaza in Tamil Nadu. The dual wins underline the company’s expanding footprint in toll‑plaza operations.

Zydus Lifesciences Faces Headwinds Shares of Zydus Lifesciences dipped following HSBC’s decision to retain a Hold rating with a target price of ₹1,100. The brokerage highlighted the U.S. launch of the drug Saroglitazar as a significant research‑and‑development milestone. While the company expects a gradual sales ramp, HSBC noted that achieving a 28‑30 % EBITDA margin over the next five years will hinge on execution. The U.S. Food and Drug Administration’s approval remains the key catalyst for the drug’s commercial success.

Mahindra & Mahindra Mixed Performance Mahindra & Mahindra’s shares fell 2 % despite a 15 % year‑on‑year rise in total sales to 1.15 lakh units. Passenger vehicle sales grew 14 % YoY, reaching 64,092 units, but exports slipped 7 % to 4,019 units. Tractor sales also declined 21 % YoY, dropping to 52,100 units from 66,111 units a year earlier. The mixed data suggests that while domestic demand remains robust, international and agricultural segments are under pressure.

SML Mahindra Sales Growth vs Share Decline SML Mahindra’s stock fell nearly 4 % even though September sales rose 18 % YoY to 1,124 units from 950 units. The disconnect between sales performance and market sentiment points to investor concerns about margins, pricing power, or broader sector dynamics.

Lemon Tree Hotels Expands in West Bengal Lemon Tree Hotels experienced a 3 % rise in share price after announcing the opening of Keys Prima in Darjeeling. The 65‑room property, managed by the group’s Carnation Hotels subsidiary, marks the company’s first hotel in the town and strengthens its presence in West Bengal.

Investors are likely to keep a close eye on brokerage calls, block deals, order wins, and regulatory developments that could influence stock volatility throughout the session.

🏛️ Background & Context

Highway Infrastructure operates in the toll‑plaza segment of India’s road network, a growing area as the government pushes for infrastructure development. Zydus Lifesciences is a major Indian pharma company with a focus on metabolic disorders; Saroglitazar is a drug targeting non‑alcoholic fatty liver disease. Mahindra & Mahindra is a diversified conglomerate with core businesses in passenger vehicles, tractors, and exports. SML Mahindra is a leading manufacturer of commercial vehicles. Lemon Tree Hotels is a mid‑scale hotel chain expanding across India.

👁️ What To Watch Next

Key developments to watch include the U.S. FDA’s decision on Saroglitazar, potential export policy changes affecting Mahindra & Mahindra, and any further contract wins for Highway Infrastructure. Investors should also monitor block‑deal activity and brokerage revisions that could sway market sentiment.